Featured
Why Novellia thinks the best biopharma data strategy starts with patients, not pipelines
“Everything that’s good for patients delivers extraordinary value for biopharma - that overlap is the entire company,” says Shashi Shankar, CEO. From symptom tracking to AI-driven normalization, Novellia builds patient-first data infrastructure that scales into biopharma-grade intelligence.
From sickness to prevention: How welfare cuts risk undermining the UK's 10-Year Health Plan
“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.
Moloch and Medicine: why good intentions built a broken system, and why CGT might fix it all (sort of)
Anis Fahandej-Sadi breaks down the big problems with current incentive structures
Finding balance in the noise
"Almost a third of over-65s will fall each year," but could nGVS represent a discreet tool against imbalance?
Sick enough: the silent struggles of sub-clinical illness in modern medicine
To live in the grey zone of sub-clinical pathology is to be unwell enough to hurt, but not enough to be heard.
In the Company of Shadows: Love, Labour, and the Long Way Through
First-generation medical students carry two textbooks - one devoted to anatomy, the other towards cultivating resilience.
Gut Feelings: Harnessing the Gut Microbiome to Manage Anxiety in Primary Care
Trillions of microbes inside us are not mere bystanders, but quiet architects of our moods.
The rise of Chinese pharmaceuticals and biotech
"These projects are more than acts of goodwill," China's Health Silk Road is as much about soft power as it is about medicine.
More than just a headache
“Pain is treated like a badge of honor" in medicine, but the cost is a workforce breaking under invisible pressure.
Artificial intelligence in skin cancer diagnosis: Improving diagnostics and reducing health disparity
"AI has already been shown to be just as, if not more, accurate than dermatologists," Dr. Alexander Green explains, as DERM proves 99.8% effective at ruling out cancer.
Martial law targets resident physicians: implications for the healthcare crisis in South Korea
Industrial relations between doctors and the state have never been worse
FDA approvals - December 2025
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
FDA Approvals - November 2025
Mitochondrial disease and mutant leukemias signal where specialty pharma is placing its biggest bets.
FDA approvals - September 2025
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
Onyx @ Jefferies: Ali Pashazadeh, CEO, Treehill Partners
"85% of failures are us having failed the molecule, not the molecule having not delivered."
Jefferies Healthcare Conference 2025 - Onyx Roundup | London Life Sciences Week 2025
Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
Onyx @ Jefferies: Lubor Gaal, CFO, Circio
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Onyx @ Jefferies: David Chang, CEO, Allogene
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
Onyx @ Jefferies: David Hung, CEO, Nuvation Bio
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
Onyx @ Jefferies: Jon Rees, CEO, MitoRx
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
Biotech's new superstructure: Vivodyne's bid to turn human tissues into scalable, searchable data
Vivodyne’s automated human-testing platform aims to deliver unprecedented scale, reproducibility, and biological fidelity in preclinical drug testing - powered by patient-derived tissues that “already know the instructions,” as CEO Andrei Georgescu puts it.
Inside Cellares’ $380M push to automate cell therapy manufacturing
With Bridgewater online and global facilities underway, Cellares is moving from platform development to commercial execution. CEO Fabian Gerlinghaus says, “Our factories can produce as many therapies as ten manual facilities - with just ten percent of the people.”
Why Allucent says its global footprint is now a competitive edge in early-stage trials
Paula Brown Stafford argues that real differentiation now comes from pairing global operations with smart, disciplined innovation. “We're adding AI as a teammate, but we still need our team to have their own expertise to ask the right questions.”
Building for zero failure: How 4G Clinical is redefining trial supply management
At 4G Clinical, David Kelleher articulates a leadership philosophy built on precision, flexibility, and the belief that execution failures in trials carry real human consequences: “We will never mis-randomize, stock out, miss dose, or compromise the blind.”
How DNAnexus is enabling precision medicine from research to the point of care
DNAnexus is pushing precision medicine out of research silos to improve care delivery. As CEO Thomas Laur puts it, “The future isn’t moving data into one big bucket. It’s moving algorithms to federated data,” enabling distributed clinical decisions at scale.
‘The moat is data’: Marc Tessier-Lavigne on building an AI-native drug company
As traditional drug discovery reaches its limits, Xaira is pushing toward a more predictive, AI-native model. CEO Marc Tessier-Lavigne says, “we’re turning this broken, artisanal endeavor into something much closer to an engineering discipline.”
Supported by
